December 2013

Chronic Pain - 2013

Report Authors
Natalie C. Taylor, Ph.D.
Michelle P. Sosa, Sc.M.
  • Pages:220
  • Tables:30
  • Figures:20
  • Citations:98
  • Drugs:62
  • Interviews:53


Despite near-term sales losses attributable to the upcoming generic erosion of several market-leading drugs, the market for chronic pain therapies will continue to present significant commercial opportunity for drug developers over the next ten years. Key factors driving growth in this market are the increasing prevalence of key population segments, including osteoarthritis pain and chronic low back pain, as well as the unmet need for safer and better-tolerated analgesics. Emerging therapies such as abuse-deterrent opioid reformulations and biologic drugs targeting nerve growth factor (NGF) are expected to have significant implications on overall market dynamics.

Questions Answered in This Report:

  *   Interviewed physicians unanimously report that the vast majority of chronic pain sufferers require more than one drug to manage their pain adequately. Which therapies currently experience the greatest use in the treatment of chronic pain? Will any of the emerging chronic pain products expected to launch over the next decade be effective enough to be used as monotherapies?

  *   Over the past fifteen years, long-acting and extended-release opioids have been used at high doses and over long treatment durations in chronic non-cancer pain patients in the United States—resulting in a drastic increase in the number of opioid-tolerant individuals and a prescription opioid abuse epidemic. Do interviewed thought leaders anticipate that the recent implementation of mandatory Risk Evaluation and Mitigation Strategy programs or the change in indication labelling for LA/ER opioids will result in more responsible prescribing practices among U.S. physicians? How are the attitudes toward prescribing opioids for chronic non-cancer pain conditions different in Europe and Japan than those in the United States?

  *   Nearly all recently launched products for the treatment of chronic pain have been reformulations of existing agents or drugs having mechanisms of action similar to those of current therapies. In addition, the pipeline for chronic pain therapies consists of many reformulations and compounds with similar mechanisms of action. What novel drug targets show the most commercial potential? Do interviewed thought leaders believe that more-specific chronic pain therapies will have truly differentiated clinical profiles, and how do they anticipate incorporating such therapies into the treatment algorithm?

  *   Companies developing antibodies against NGF for the treatment of chronic pain are expected to resume large clinical trials in osteoarthritis pain and other chronic non-cancer pain conditions in 2014. Now that the safety risks associated with anti-NGF therapies have become clearer, what types of patients are expected to be the most likely candidates for treatment?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 53 country-specific interviews with thought-leading physicians.

Epidemiology: Region-specific prevalence estimates for key chronic pain populations for 2012, 2017, and 2022: arthritic pain (osteoarthritic and rheumatoid), cancer pain (severe, neuropathic, and metastatic bone cancer pain), chronic daily headache, chronic low back pain, fibromyalgia, chronic migraine, painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN).

Emerging therapies: Phase II: 42 drugs; Phase III/preregistration/registered: 15 drugs. Coverage of 5 select preclinical and Phase I products.

Market forecast features: We segment key chronic pain populations in the base year (2012) and forecast population sizes and total chronic pain drug sales for therapies through 2022.

Fill out the form below to contact sales.

Search Reports

Mentioned in this report:

  • - AbbVie
  • - Acorda Therapeutics
  • - Actavis
  • - Aestus
  • - Afferent Pharmaceuticals
  • - Alkermes
  • - Alza
  • - Arcion
  • - Array BioPharma
  • - AskAt
  • - Astellas
  • - AstraZeneca
  • - Avanir
  • - Bayer HealthCare
  • - BioAlliance Pharma
  • - BioDelivery Sciences International
  • - Boehringer Ingelheim
  • - Collegium Pharmaceuticals
  • - Convergence Pharmaceuticals
  • - Creabilis Therapeutics
  • - Daiichi Sankyo
  • - Dainippon Sumitomo
  • - Depomed
  • - Eli Lilly
  • - Endo Pharmaceuticals
  • - Esteve
  • - Forest Laboratories
  • - Glenmark
  • - GrĂĽnenthal
  • - GW Pharmaceuticals
  • - Hisamitsu Pharmaceuticals
  • - Horizon Pharma
  • - Idea AG
  • - Immune Pharmaceuticals
  • - Iroko Pharmaceuticals
  • - Janssen
  • - Janssen-Cilag
  • - Johnson & Johnson
  • - Kyowa Hakko Kirin
  • - Labopharm
  • - Laboratorios Almirall
  • - Mallinckrodt
  • - Meda AB
  • - Merck & Co., Inc.
  • - Mundipharma
  • - Napp Pharmaceuticals
  • - Nektar
  • - NeurAxon
  • - Newron Pharmaceuticals
  • - Novartis
  • - Nuvo Research
  • - Olatec Industries
  • - Pfizer
  • - Purdue Pharma
  • - Recordati SpA
  • - Relmada Therapeutics
  • - Rottapharm Madaus
  • - Sanofi
  • - Shionogi
  • - SK Biopharmaceuticals
  • - Synthetic Biologics
  • - Taisho Pharmaceutical
  • - Takeda
  • - Teva
  • - Theravance
  • - Vernalis
  • - Xenoport
  • - Zalicus
  • - Zogenix
Decision Resources Group brands include: